DOCSLIB.ORG

Update on the Mechanism of Action of Topical Prostaglandins for Intraocular Pressure Reduction Carol B

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Update on the Mechanism of Action of Topical Prostaglandins for Intraocular Pressure Reduction Carol B SURVEY OF OPHTHALMOLOGY VOLUME 53 SUPPLEMENT 1 NOVEMBER 2008 Update on the Mechanism of Action of Topical Prostaglandins for Intraocular Pressure Reduction Carol B. Toris, PhD,1 B’Ann T. Gabelt, MS,2 and Paul L. Kaufman, MD2 1Department of Ophthalmology and Visual Sciences, University of Nebraska Medical Center, Omaha, Nebraska, USA; and 2Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, Wisconsin, USA Abstract. A decade has passed since the first topical prostaglandin analog was prescribed to reduce intraocular pressure (IOP) for the treatment of glaucoma. Now four prostaglandin analogs are available for clinical use around the world and more are in development. The three most efficacious of these drugs are latanoprost, travoprost, and bimatoprost, and their effects on IOP and aqueous humor dynamics are similar. A consistent finding is a substantial increase in uveoscleral outflow and a less consistent finding is an increase in trabecular outflow facility. Aqueous flow appears to be slightly stimulated as well. Prostaglandin receptors and their associated mRNAs have been located in the trabecular meshwork, ciliary muscle, and sclera, providing evidence that endogenous prostaglandins have a functional role in aqueous humor drainage. Earlier evidence found that topical PG analogs release endogenous prostaglandins. One well-studied mechanism for the enhancement of outflow by prostaglandins is the regulation of matrix metalloproteinases and remodeling of extracellular matrix. Other proposed mechanisms include widening of the connective tissue-filled spaces and changes in the shape of cells. All of these mechanisms alter the permeability of tissues of the outflow pathways leading to changes in outflow resistance and/or outflow rates. This review summarizes recent (since 2000) animal and clinical studies of the effects of topical prostaglandin analogs on aqueous humor dynamics and recent cellular and molecular studies designed to clarify the outflow effects. (Surv Ophthalmol 53:S107--S120, 2008. Ó 2008 Elsevier Inc. All rights reserved.) Key words. aqueous humor intraocular pressure matrix metalloproteinases prostaglandin trabecular outflow uveoscleral outflow All of the clinically available drugs for the treatment through the uveoscleral outflow pathway but signif- of elevated intraocular pressure (IOP) have direct icant effects on trabecular outflow facility also have 67,85 effects on one or more parameters of aqueous been reported. Three PGF2a analogs (bimato- humor dynamics. IOP usually is reduced by slowing prost, latanoprost, and travoprost) are approved for the production rate of aqueous humor, by de- glaucoma therapy in the United States, one addi- creasing the resistance to flow through the trabec- tional analog (unoprostone) is prescribed in Japan ular meshwork, by increasing drainage through the and a new analog (tafluprost) is in clinical trials in uveoscleral outflow pathway, or by a combination of Japan. Travoprost and latanoprost are ester pro- these mechanisms. Currently, the most effective drugs of PGF2a. Bimatoprost is the amide prodrug 86 outflow drugs approved for clinical use are prosta- of 17-phenyl-PGF2a and has been classified 86 glandin (PG) F2a analogs. These drugs reduce IOP by some as a prostamide, although this classifica- by stimulation of aqueous humor drainage primarily tion has been somewhat controversial.7,37,56--58,86,87 S107 Ó 2008 by Elsevier Inc. 0039-6257/08/$--see front matter All rights reserved. doi:10.1016/j.survophthal.2008.08.010 S108 Surv Ophthalmol 53 (Suppl 1) November 2008 TORIS ET AL 44 23 Unoprostone is an analog of a pulmonary metabo- agonists butaprost and 8-iso PGE2 (Table 1). 26 lite of PGF2a and sometimes labeled a docosanoid. Exceptions do exist. One drop of 17-phenyl trinor 8- Tafluprost is a difluoroprostaglandin derivative of iso PGE2 and the selective EP4 receptor agonist 3,7- 62 PGF2a. Agonists of DP, EP, and TP receptors have dithia PGE1 increased outflow facility sufficiently in been or are being investigated in animal models for normotensive monkey eyes to account for most, if their IOP efficacy and potential as new glaucoma not all of the IOP reduction (Kharlamb, ARVO 2004 therapeutic drugs. None of these agonists has yet to abstract 1035, Table 1). An older study found an be approved for clinical use. increase in outflow facility at 4 hours after one 35 This review summarizes recent (since 2000) topical drop of PGF2a. animal and clinical English-language studies of the One potential reason for the apparent differences effects of topical PG agonists on aqueous humor in trabecular outflow facility effect among the dynamics and recent cellular and molecular studies various PG agonists is the method of measurement. designed to clarify the outflow effects. Two noninvasive methods, tonography and fluoro- photometry, and two invasive methods, two-level constant pressure perfusion and isotope accumula- Aqueous Humor Dynamics tion, are used to make the assessment. All methods measure trabecular outflow facility, but confound- Latanoprost, travoprost, and bimatoprost pro- ing factors are known to exist, including ocular duce similar increases in uveoscleral outflow of rigidity (a measure of eye stiffness), pseudofacility several-fold. Increases in trabecular outflow facility (the facility of flow of aqueous humor from the also have been reported but this finding has not posterior to anterior chamber resulting from the been found consistently (Table 1). Unoprostone, probe-induced increase in IOP), and uveoscleral the least efficacious of the four compounds, appears outflow facility. The name of the measured variable to have little effect on uveoscleral outflow in trabecular outflow facility is not entirely accurate humans. Rather it works mainly by increasing because of the inclusion of these other factors in trabecular outflow facility.69 The new fluoroprosta- the various measurements. All of the measurement glandin F , tafluprost, increases uveoscleral outflow 2a techniques assume that uveoscleral outflow facility is and aqueous flow in monkeys62 but has yet to be very small and affected little by the measurement studied in humans. Earlier studies13,89 have re- itself. This assumption is based on monkey stud- ported that the topical PG analogs release endoge- ies8,68 reporting that uveoscleral outflow is relatively nous prostaglandins that may contribute to the pressure-independent. However, if an experimental observed ocular hypotensive effects. Tafluprost in manipulation were to increase uveoscleral outflow mice reportedly works in part through FP receptor- facility, this could be interpreted erroneously, as an mediated prostaglandin production acting through increase in trabecular outflow facility. It is thought the prostanoid EP receptor.49 Studies published 3 by some that PGs increase uveoscleral outflow between 2000 and 2008 of FP, DP, and EP receptor facility but this has yet to be proven experimentally. agonists and their effects on aqueous humor These methods may not detect changes in trabecu- dynamics in humans and nonhuman primates are lar outflow facility if the changes are overshadowed summarized in Table 1. Studies predating 2000 are by strong effects on uveoscleral outflow and/or found in an earlier review.67 uveoscleral outflow facility. The length of time of treatment could be another TRABECULAR OUTFLOW FACILITY factor contributing to the differing effects of PGs on Trabecular outflow facility is not always increased trabecular outflow facility. The immediate IOP following topical treatment with PG analogs but effects that occur from a single dose of a PG analog evidence is building that the effect is real and not may be mediated by cellular mechanisms different unique to any one drug of this class. Latanoprost, from those that occur after repeated applications or travoprost, bimatoprost, and unoprostone all have continuous exposure.9,83,90 Therefore, findings been found to significantly increase trabecular from multiple doses of each PG should be com- outflow facility in at least one clinical study pared before concluding that one PG analog acts (Table 1). through mechanisms different from all others. Compared to humans, the trabecular meshwork Mice are being used with increasing frequency to of monkeys seems to be less affected by PG analogs. evaluate aqueous humor dynamics because of their Trabecular outflow facility was unchanged following potential for genetic manipulation in addition to multiple topical treatments of monkeys with PGF2a- their ocular similarities to humans. These animals isopropyl ester,22 tafluprost,62 and travoprost,71 the exhibit increases in outflow facility 2 hours after one DP receptor agonist AL-6598,72 and EP receptor 4-ml drop of latanoprost.18 Several limitations to TOPICAL PROSTAGLANDINS AND AQUEOUS HUMOR DYNAMICS TABLE 1 Studies of Aqueous Humor Dynamics in Humans and Nonhuman Primates Treated with Prostaglandin Analogs Published from 2000 to 2008 Type and Number Duration of Analog of Subjects Treatment IOP Fa CPev Fu Reference FP receptor analogs, prostamides Bimatoprost ONT volunteers QD Â 2 days Y(day) [(day) [day [day Brubaker et al, 200111 (n 5 25) QD Â 3 days Y(night) [(night) OHT or POAG patients QD Â 7 days Y4 [ [Christiansen et al, (n 5 29) 200416 ONT volunteers QD Â 7 days Y4 [ [Lim et al, 200838 (n 5 30) Latanoprost OHT patients (n 5 30) QD Â 7 days Y4 44[Toris et al, 200173 OHT or POAG patients QD Â 14 days Y4 [ Dinslage et al, 200420 (n 5 30) ONT volunteers QD Â 7 days Y4 [ [Lim et al , 200838 (n 5 30) 15-keto latanoprost Cynomolgus,
Load more

Recommended publications
  • 202514Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 202514Orig1s000 CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW(S) OFFICE OF CLINICAL PHARMACOLOGY REVIEW NDA: 202-514 Submission Date(s): January 7, 2011 Proposed Brand Name TBD Generic Name Tafluprost Primary Reviewer Yongheng Zhang, Ph.D. Team Leader Philip M. Colangelo, Pharm.D., Ph.D. OCP Division DCP4 OND Division DTOP Applicant MERCK & CO., Inc. Relevant IND(s) 062690 Submission Type; Code 1S(NME) Formulation; Strength(s) Tafluprost 0.0015% Ophthalmic Solution Indication For the reduction of elevated intraocular pressure in open-angle glaucoma or ocular hypertension Dosage and Administration One drop of Tafluprost 0.0015% ophthalmic solution in the conjunctival sac of the affected eye(s) once daily in the evening TABLE OF CONTENTS 1. EXECUTIVE SUMMARY .................................................................................................................. 2 1.1. RECOMMENDATION ....................................................................................................................... 3 1.2. PHASE IV COMMITMENTS............................................................................................................. 3 1.3. SUMMARY OF IMPORTANT CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS FINDINGS.. 3 2. QUESTION BASED REVIEW ...........................................................................................................4 2.1. GENERAL ATTRIBUTES OF THE DRUG .........................................................................................
    [Show full text]
  • Blood-Aqueous Barrier Changes After the Use of Prostaglandin Analogues in Patients with Pseudophakia and Aphakia a 6-Month Randomized Trial
    CLINICAL SCIENCES Blood-Aqueous Barrier Changes After the Use of Prostaglandin Analogues in Patients With Pseudophakia and Aphakia A 6-Month Randomized Trial Enyr S. Arcieri, MD; Alessandro Santana, MD; Fabiano N. Rocha, MD; Gustavo L. Guapo, MD; Vital P. Costa, MD Objectives: To investigate the effects of prostaglandin throughout follow-up (P Ͻ .02). Four latanoprost- analogues on the blood-aqueous barrier and to evaluate treated eyes, 1 bimatoprost-treated eye, and 1 travoprost- the occurrence of cystoid macular edema in aphakic or treated eye developed cystoid macular edema; all cases pseudophakic patients with glaucoma. resolved after discontinuation of the prostaglandin ana- logue and treatment with topical diclofenac sodium. Mean Methods: In this randomized, masked-observer, 6-month intraocular pressure reductions after 6 months were higher clinical trial, patients with primary open-angle, pseudo- for the latanoprost (26%), bimatoprost (28%), and tra- phakic, or aphakic glaucoma were treated once daily with voprost (29%) groups than for the control (3%) and uno- bimatoprost (n=16), latanoprost (n=15), or travoprost prostone (14%) groups (PϽ.05). Bimatoprost induced (n=17) or twice daily with unoprostone (n=16) or lu- significantly higher hyperemia scores than latanoprost, bricant drops (control group) (n=16). Blood-aqueous bar- unoprostone, and placebo (PϽ.01). rier status, which was assessed using a laser flare meter; intraocular pressure; the occurrence of angiographic cys- toid macular edema; and conjunctival hyperemia were Conclusion: Bimatoprost, latanoprost, and travoprost use evaluated. may lead to disruption of the blood-aqueous barrier in patients with pseudophakia and aphakia. Results: Mean flare values were significantly higher in the bimatoprost, latanoprost, and travoprost groups Arch Ophthalmol.
    [Show full text]
  • Eyelash Growth Induced by Topical Prostaglandin Analogues, Bimatoprost, Tafluprost, Travoprost, and Latanoprost in Rabbits
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS ORIGINAL ARTICLE Volume 00, Number 0, 2013 ª Mary Ann Liebert, Inc. DOI: 10.1089/jop.2013.0075 Eyelash Growth Induced by Topical Prostaglandin Analogues, Bimatoprost, Tafluprost, Travoprost, and Latanoprost in Rabbits Ama´lia Turner Giannico,1 Leandro Lima,1 Heloisa Helena Abil Russ,2 and Fabiano Montiani-Ferreira1 Abstract Purpose: Prostaglandin analogues (PGA) are ocular hypotensive agents used for the treatment of glaucoma. Hypertrichosis of the eyelashes has been reported in humans as a side effect. Eyelash growth was investigated with clinical trials in people using bimatoprost. Scattered reports of eyelash growth during the treatment of glaucoma with other PGA are also found in the literature. We investigated the effect of 4 different topical PGA on eyelash length. Methods: Forty New Zealand white rabbits were divided into 4 groups and received daily topical application of bimatoprost, tafluprost, travoprost, and latanoprost in the left eye for 4 weeks. The right eye received no treatment. Eyelash length was measured in both eyes before and after treatment using a stainless steel digital caliper. Results: Bimatoprost and tafluprost groups had significant increases in eyelash length. We did not observe significant eyelash growth in rabbits receiving travoprost and latanoprost after 1 month of treatment. Conclusions: Today, only bimatoprost is approved for growing eyelashes, and our research shows that ta- fluprost could be further explored by the cosmetic and pharmaceutical industry. Additional research using travoprost and latanoprost as agents for eyelash growth should be performed in the future using prolonged treatment periods to determinate whether or not these PGA induce eyelash growth, and investigate other possible side effects.
    [Show full text]
  • 16171145.Pdf
    CORE Metadata, citation and similar papers at core.ac.uk Provided by Radboud Repository PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/86683 Please be advised that this information was generated on 2017-12-06 and may be subject to change. OBSTETR GYNEC European Journal of Obstetrics & Gynecology ELSEV and Reproductive Biology 61 (1995) 171-173 Case report Critical limb ischemia after accidental subcutaneous infusion of sulprostone Yvonne W.C.M. de Koninga, Peter W. Plaisierb, I. Leng Tanc, Fred K. Lotgering*a aDepartment o f Obstetrics and Gynaecology, Erasmus University, School o f Medicine and Health Sciences, EUR EE 2283, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands bDepartment o f General Surgery, Erasmus University, School o f Medicine and Health Sciences, EUR EE 2283, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands cDepartment o f Radiology, Erasmus University, School o f Medicine and Health Sciences, EUR EE 2283, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands Received 23 September 1994; accepted 20 January 1995 Abstract A 34-year-old patient was treated with constant intravenous infusion of sulprostone because of postpartum hemorrhage from a hypotonic uterus. The arm in which sulprostone had been infused was painful 23 h after infusion. A day later, the arm was found to be blueish, edematous and extremely painful as a result of arterial spasm. The vasospasm was probably caused by accidental subcutaneous infusion of sulprostone as a result of a displaced intravenous catheter.
    [Show full text]
  • Structure-Based Discovery of Mpges-1 Inhibitors Suitable For
    www.nature.com/scientificreports OPEN Structure-based discovery of mPGES-1 inhibitors suitable for preclinical testing in wild-type Received: 4 January 2018 Accepted: 9 March 2018 mice as a new generation of anti- Published: xx xx xxxx infammatory drugs Kai Ding1,2,3, Ziyuan Zhou1,2, Shurong Hou2, Yaxia Yuan1,2,4, Shuo Zhou1,2, Xirong Zheng2, Jianzhong Chen1,2, Charles Loftin2, Fang Zheng1,2 & Chang-Guo Zhan1,2,4 Human mPGES-1 is recognized as a promising target for next generation of anti-infammatory drugs without the side efects of currently available anti-infammatory drugs, and various inhibitors have been reported in the literature. However, none of the reported potent inhibitors of human mPGES-1 has shown to be also a potent inhibitor of mouse or rat mPGES-1, which prevents using the well-established mouse/rat models of infammation-related diseases for preclinical studies. Hence, despite of extensive eforts to design and discover various human mPGES-1 inhibitors, the promise of mPGES-1 as a target for the next generation of anti-infammatory drugs has never been demonstrated in any wild-type mouse/rat model using an mPGES-1 inhibitor. Here we report discovery of a novel type of selective mPGES-1 inhibitors potent for both human and mouse mPGES-1 enzymes through structure-based rational design. Based on in vivo studies using wild-type mice, the lead compound is indeed non-toxic, orally bioavailable, and more potent in decreasing the PGE2 (an infammatory marker) levels compared to the currently available drug celecoxib. This is the frst demonstration in wild-type mice that mPGES-1 is truly a promising target for the next generation of anti-infammatory drugs.
    [Show full text]
  • Differential Activity and Clinical Utility of Latanoprost in Glaucoma and Ocular Hypertension
    Clinical Ophthalmology Dovepress open access to scientific and medical research Open Access Full Text Article REVIEW Differential activity and clinical utility of latanoprost in glaucoma and ocular hypertension Fernanda Pacella Background: The purpose of this study was to demonstrate the hypotensive efficacy and tolerability Paolo Turchetti of latanoprost when used as monotherapy and as polytherapy associated with antiglaucomatous Valentina Santamaria medication proven to be ineffective in keeping intraocular pressure under control. David Impallara Methods: Three hundred and thirty-seven patients (672 eyes) affected by primary open-angle Gianpaolo Smaldone glaucoma and intraocular hypertension were recruited over a period of 10 years from the Chiara Brillante Glaucoma Centre, Department of Ophthalmological Sciences, University of Rome “Sapienza”, and treated, subject to informed consent, with latanoprost 0.005% alone or in combination Aloisa Librando with other ocular hypotensive drugs. The patients were followed during this period at regular Angela Damiano intervals, with determination of visual field, fundus oculi, visual acuity, and eventual onset of Jose Pecori-Giraldi local and systemic side effects. Elena Pacella Results: Latanoprost used as monotherapy and as polytherapy renders possible optimal and Department of Sense Organs, durable control of intraocular pressure in the form of one antiglaucomatous drug because it can University of Rome “Sapienza”, substitute for one or more drugs and obtain the same hypotensive effect. Roma,
    [Show full text]
  • New York State Medicaid Drug Utilization Board Meeting Agenda
    New York State Medicaid Drug Utilization Board Meeting Agenda The Drug Utilization (DUR) Board will meet April 24, 2014, from 9:00 a.m. to 4:30 p.m., Meeting Room 6, Concourse, Empire State Plaza, Albany, New York Agenda Items Preferred Drug Program (PDP) The DUR Board will review therapeutic classes, described and listed below, as they pertain to the PDP. The therapeutic classes to be reviewed contain new relevant clinical and/or financial information. Therapeutic classes not included on this agenda may be reviewed at a later date. The Board will review new clinical and financial information as required, to recommend preferred and non-preferred drugs. ^ The Board will only consider clinical information which is new since the previous review of the therapeutic class and then consider financial information. New clinical information may include a new drug or drug product information, new indications, new safety information or new published clinical trials (comparative evidence is preferred, or placebo controlled when no head-to-head trials are available). Information in abstract form alone, posters, or unpublished data are poor quality evidence for the purpose of re-review and submission is discouraged. Those wishing to submit new clinical information must do so in an electronic format by April 9, 2014 or the Board may not have ample time to review the information. ^ The current preferred and non-preferred status of drugs subject to the Preferred Drug List (PDL) may be viewed at https://newyork.fhsc.com/downloads/providers/NYRx_PDP_PDL.pdf
    [Show full text]
  • Antiluteogenic Effects of Serial Prostaglandin F2α Administration in Mares
    ANTILUTEOGENIC EFFECTS OF SERIAL PROSTAGLANDIN F2α ADMINISTRATION IN MARES Thesis Presented in partial fulfillment of the requirements for the Master of Science in the Graduate School of The Ohio State University Elizabeth Ann Coffman Graduate ProGram in Comparative and Veterinary Medicine The Ohio State University 2013 Thesis committee: Carlos R.F. Pinto PhD, MV, DACT; Dissertation Advisor Marco A. Coutinho da Silva PhD, MV, DACT; Academic Advisor Christopher Premanandan PhD, DVM, DACVP Copyright by Elizabeth Ann Coffman 2013 Abstract For breedinG manaGement and estrus synchronization, prostaGlandin F2α (PGF) is one of the most commonly utilized hormones to pharmacologically manipulate the equine estrous cycle. There is a general supposition a sinGle dose of PGF does not consistently induce luteolysis in the equine corpus luteum (CL) until at least five to six days after ovulation. This leads to the erroneous assumption that the early CL (before day five after ovulation) is refractory to the luteolytic effects of PGF. An experiment was desiGned to test the hypotheses that serial administration of PGF in early diestrus would induce a return to estrus similar to mares treated with a sinGle injection in mid diestrus, and fertility of the induced estrus for the two treatment groups would not differ. The specific objectives of the study were to evaluate the effects of early diestrus treatment by: 1) assessing the luteal function as reflected by hormone profile for concentration of plasma progesterone; 2) determininG the duration of interovulatory and treatment to ovulation intervals; 3) comparing of the number of pregnant mares at 14 days post- ovulation. The study consisted of a balanced crossover desiGn in which reproductively normal Quarter horse mares (n=10) were exposed to two treatments ii on consecutive reproductive cycles.
    [Show full text]
  • Effect of Bimatoprost on Intraocular Pressure in Prostaglandin FP Receptor Knockout Mice
    Effect of Bimatoprost on Intraocular Pressure in Prostaglandin FP Receptor Knockout Mice Jonathan G. Crowston,1 James D. Lindsey,1 Christy A. Morris,1 Larry Wheeler,2 Felipe A. Medeiros,1 and Robert N. Weinreb1 PURPOSE. To determine the effect of bimatoprost on intraocular ing are not known, it has been suggested that bimatoprost pressure in the prostaglandin FP receptor knockout mouse. fundamentally differs from latanoprost, by lowering IOP ETHODS ␮ ␮ through mechanisms that are independent of FP receptor sig- M . The IOP response to a single 1.2- g(4 L) dose of 5 bimatoprost was measured in the treated and untreated fellow naling. However, there is considerable controversy regarding eyes of homozygote (FPϩ/ϩ, n ϭ 9) and heterozygote (FPϮ, n the role of FP receptor signaling, because bimatoprost has ϭ been shown to bind and activate the FP receptor in cultured 10) FP-knockout mice, as well as in wild-type C57BL/6 mice 6 (FPϩ/ϩ, n ϭ 20). Serial IOP measurements were also per- human trabecular meshwork and human ciliary muscle cells. Measurement of aqueous humor dynamics in the mouse eye formed after topical bimatoprost in a separate generation of 7 homozygous FP-knockout mice and wild-type littermate con- has been detailed recently. The FP knockout mouse, gener- trol animals (n ϭ 4 per group). Aqueous humor protein ated by homologous translocation with a target vector that ␤ concentrations were measured to establish the state of the replaces the second exon of the FP gene with the -galactosi- blood–aqueous barrier. Tissue, aqueous humor and vitreous dase and neomycin-resistance gene, was produced to demon- strate the critical role of the interaction of PGF2␣ with FP concentrations of bimatoprost, latanoprost, and their C-1 free 8 acids were determined by liquid chromatography and tandem receptors in the initiation of parturition in pregnant mice.
    [Show full text]
  • Effect of Prostanoids on Human Platelet Function: an Overview
    International Journal of Molecular Sciences Review Effect of Prostanoids on Human Platelet Function: An Overview Steffen Braune, Jan-Heiner Küpper and Friedrich Jung * Institute of Biotechnology, Molecular Cell Biology, Brandenburg University of Technology, 01968 Senftenberg, Germany; steff[email protected] (S.B.); [email protected] (J.-H.K.) * Correspondence: [email protected] Received: 23 October 2020; Accepted: 23 November 2020; Published: 27 November 2020 Abstract: Prostanoids are bioactive lipid mediators and take part in many physiological and pathophysiological processes in practically every organ, tissue and cell, including the vascular, renal, gastrointestinal and reproductive systems. In this review, we focus on their influence on platelets, which are key elements in thrombosis and hemostasis. The function of platelets is influenced by mediators in the blood and the vascular wall. Activated platelets aggregate and release bioactive substances, thereby activating further neighbored platelets, which finally can lead to the formation of thrombi. Prostanoids regulate the function of blood platelets by both activating or inhibiting and so are involved in hemostasis. Each prostanoid has a unique activity profile and, thus, a specific profile of action. This article reviews the effects of the following prostanoids: prostaglandin-D2 (PGD2), prostaglandin-E1, -E2 and E3 (PGE1, PGE2, PGE3), prostaglandin F2α (PGF2α), prostacyclin (PGI2) and thromboxane-A2 (TXA2) on platelet activation and aggregation via their respective receptors. Keywords: prostacyclin; thromboxane; prostaglandin; platelets 1. Introduction Hemostasis is a complex process that requires the interplay of multiple physiological pathways. Cellular and molecular mechanisms interact to stop bleedings of injured blood vessels or to seal denuded sub-endothelium with localized clot formation (Figure1).
    [Show full text]
  • Effect of Latanoprost Or 8-Iso Prostaglandin E2 Alone and in Combination on Intraocular Pressure in Glaucomatous Monkey Eyes
    LABORATORY SCIENCES Effect of Latanoprost or 8-iso Prostaglandin E2 Alone and in Combination on Intraocular Pressure in Glaucomatous Monkey Eyes Rong-Fang Wang, MD; Steven M. Podos, MD; Janet B. Serle, MD; Thomas W. Mittag, PhD; F. Ventosa, MD; Bernard Becker, MD Objective: To evaluate the possible additivity of the ef- duction of IOP of 4.0 ± 0.6 mm Hg was produced when fects of latanoprost and 8-iso prostaglandin E2 (8-iso PGE2) 8-iso PGE2 was added to latanoprost and of 3.0 ± 0.7 on intraocular pressure (IOP) in monkey eyes with laser- mm Hg was produced when latanoprost was added to 8-iso induced glaucoma. PGE2 on day 13 before the morning dosing. Combina- tion therapy with both agents caused maximum IOP re- Methods: The IOP was measured hourly for 6 hours be- ductions from baseline of 11.3 ± 3.0 mm Hg (33%) (P,.05) ginning at 9:30 AM on day 1 (baseline day), days 6 and 7 (latanoprost with 8-iso PGE2 added) and of 9.8 ± 1.3 , (single-agent therapy), and days 13 and 14 (combination mm Hg (31%) (P .01) (8-iso PGE2 with latanoprost added) therapy with both agents). Following 1 day of baseline mea- on day 14. surement, 4 monkeys with unilateral glaucoma received monotherapy twice daily with either 1 drop of 0.005% la- Conclusion: Latanoprost and 8-iso PGE2 have an addi- tanoprost, or 0.1% 8-iso PGE2, 25 µL, at 9:30 AM and 3:30 tive effect on IOP in glaucomatous monkey eyes.
    [Show full text]
  • New Zealand Data Sheet 1. Product Name 2. Qualitative
    NEW ZEALAND DATA SHEET BIMATOPROST MULTICHEM 1. PRODUCT NAME Bimatoprost multichem 0.3 mg/mL eye drops 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each mL contains 0.3 mg bimatoprost. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Bimatoprost multichem eye drops are a clear, isotonic, colourless, sterile ophthalmic solution. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Bimatoprost multichem is indicated as monotherapy for the reduction of elevated intraocular pressure (IOP) in patients with chronic glaucoma or ocular hypertension; or as adjunctive therapy in patients not adequately controlled on other agents. 4.2 Dose and method of administration Monotherapy The recommended dose is one drop of Bimatoprost multichem in the affected eye(s) once daily, administered in the evening. Adjunctive therapy The recommended dose is one drop of Bimatoprost multichem in the affected eye(s) once daily, administered in the evening. More frequent administration has not been shown to provide increased efficacy. If more than one topical ophthalmic medication is to be used, the other medication should not be used within 5 minutes of using Bimatoprost multichem eye drops. In order to minimise systemic absorption of Bimatoprost multichem eye drops, patients should be instructed to apply pressure to the tear duct immediately following administration of the drug. Paediatric use Safety and effectiveness in patients below 18 years of age has not been established. Use in elderly No dosage adjustment in elderly patients is necessary. 4.3 Contraindications Bimatoprost multichem eye drops are contraindicated in patients with hypersensitivity to bimatoprost or to any component of the medication.
    [Show full text]